Home / Innere Medizin / Onkologie / Fortschritte beim metastasierten Mammakarzinom

Fortschritte beim metastasierten Mammakarzinom

Prim. Univ.-Prof. Dr. Andreas Petzer, Onkologie und Hämatologie, Ordensklinikum Linz, diskutiert die relevanten Mammakarzinom-Studien im metastasierten Setting zu CDK-4/6-Inhibitoren, aber auch neuen Substanzen, die einen Überlebensvorteil gezeigt haben.

Quelle: ASCO Annual Meeting 2018

Behandelte Abstracts in diesem Video:

Slamon DJ et al., Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): Results from MONALEESA-3.

https://meetinglibrary.asco.org/record/158547/abstract

Neven P et al., Abemaciclib for pre/perimenopausal women with HR+, HER2- advanced breast cancer. Abstract 1002

https://meetinglibrary.asco.org/record/160554/abstract

Turner NC et al., Genetic landscape of resistance to CDK4/6 inhibition in circulating tumor DNA (ctDNA) analysis of the PALOMA3 trial of palbociclib and fulvestrant versus placebo and fulvestrant. Abstract 1001

https://meetinglibrary.asco.org/record/158534/abstract

Baselga J et al., Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. Abstract LBA 1006

https://meetinglibrary.asco.org/record/158535/abstract

Schmid P et al., AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial. Abstract 1007

https://meetinglibrary.asco.org/record/158551/abstract

Dent RA et al., LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line Ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC). Abstract 1009

https://meetinglibrary.asco.org/record/152362/abstract

XU B et al., Phase III multicenter, randomized study of utidelone plus capecitabine versus capecitabine alone for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer. Abstract 1003

https://meetinglibrary.asco.org/record/158550/abstract

LOGIN

Login

Passwort vergessen?